Joe Roberts of Health Tech World recently interviewed Affect’s CEO, Kristin Muhlner, about the future of addiction treatment and how digital tools will play a part in it. A wide range of topics are covered in the article, including Affect’s treatment model with gamification and contingency management, the future of generative AI, how care can…
News
Media mentions and company announcements.
Newsmedia Report on Affect’s Series A Funding
Multiple news stories have been published covering our recent announcement of our $16 million series A fundraising round. Here are a few: Fortune Magazine makes note of it in their Term Sheet Newsletter. Axios’s Dan Primack included it in Pro Rata. Joanna Glasner covered the investment in an article for Crunchbase. Marissa Plescia wrote an…
Delivering Next Generation Addiction Recovery, Affect Therapeutics Raises $16 Million in Series A Funding Led by ARTIS Ventures
McLean, VA- July 12, 2023 – Affect Therapeutics (“Affect”), a company reimagining addiction treatment for the digital age, today announces a $16 million Series A led by TechBio-focused ARTIS Ventures with additional participation from previous investors AlleyCorp and CityLight, as well as new investments from LifeArc Ventures, Samsung Next, and What If Ventures. The funding…
Affect Launches New Program for Cannabis Use Disorder
In the United States, the prevalence of cannabis use disorder (CUD) has been on the rise, likely driven by increased access to highly potent new products. According to the National Survey on Drug Use and Health, nearly 6 percent of adults and teens qualify as having CUD. In response, Affect Therapeutics is pleased to announce…
Affect Therapeutics has the highest level of CARF Accreditation
We’re thrilled to announce that, in recognition of our commitment to quality care delivery, Affect has received accreditation from CARF International. Individuals seeking treatment, health insurance payers, governmental agencies, and the public at-large recognize CARF accreditation as a demonstration of accountability and conformance to standards that promote excellence in treatment of Substance Use Disorders. We…
CARF Survey
A survey team from CARF International* will be visiting Affect on 10/10/22 to 10/11/22 We invited the surveyors to evaluate how well we meet international standards for quality. The survey will tell us what we are doing well and ways we might improve. As a result of this survey, we may earn accreditation. As part…
Affect Therapeutics Aims to Curb Stimulant Addiction: Treatment Magazine
Affect Therapeutics Aims to Curb Stimulant Addiction: Treatment Magazine Jason Langendorf writes in Treatment Magazine about Affect’s all-digital treatment program and its roots in contingency management and compulsion loops to activate the brain’s rewards systems. Affect Therapeutics is an integrated recovery program accessed through a proprietary smartphone app, allowing clients to visit counselors and doctors…
Rewarding recovery: how California will pay addicts to give up drugs – Financial Times
Patti Waldmeir writes in the Financial Times about California’s new program for contingency management to address the stimulant addiction crisis, and talked to Affect’s CEO, Kristin Muhlner, about our digital recovery app. Affect Therapeutics is a digital treatment app for methamphetamine, crack and cocaine addiction that uses micropayments — as well as more traditional forms…
This Startup Just Raised $6 Million For An App That Helps Treat Addiction – Forbes
Jair Hilburn writes in Forbes about Affect’s successful close of a funding round to bring its stimulant addiction treatment smartphone app to market. Read more below: Affect Therapeutics, a company working to treat stimulant use disorder through mobile technology, announced Tuesday that it has raised $6 million in a seed investment round. Investors in the…
SUD Stakeholders’ Call to Payers: Contingency Management Key to Treating Stimulant Use Disorder – Behavioral Health Business
In this article for Behavioral Health Business, Bailey Bryant goes deep into issues with insurance companies and behavioral health providers around contingency management, which is shown to be the most effective method in treating stimulant use disorders – and is central in Affect’s approach. Affect’s CEO, Kristin Muhlner, speaks to how getting payer support is…